The frequency of RCCs with respect to the total number of patients per exon showed a higher RCC rate for patients with a mutation located in the 5’ part (exon 4–8, 14/69 patients, 20.3%, total subgroup: 56.1±16.2 years) compared to those with a mutation in the 3’ part (exon 10–14, 13/93 patients; 14.0%, total subgroup: 57.4±16.3 years) of FLCN (p-value 0.30, odds ratio 1.56197, 95% CI 0.63–3.92). This evidence concerns the gene FLCN and renal cell adenocarcinoma.